CJC-1295 and Ipamorelin: Why They Are Studied Together

Two doors into the same room

Your body already makes growth hormone. It releases it in bursts, mostly at night, and the size of those bursts falls with age.

There are two separate switches controlling that release, and this pair presses one each.

CJC-1295 imitates growth hormone releasing hormone — the signal from the brain that tells the pituitary gland to release a pulse. Ipamorelin works on a different receptor entirely, the one that responds to ghrelin, a hormone usually associated with hunger. That receptor also triggers growth hormone release, through a separate pathway.

Pressing two different switches produces a larger response than pressing either one harder. That is the reasoning behind the pairing, and it is a sound one.

What the human data shows

This is the unusual part. Most research peptides have no human trial data at all. CJC-1295 does.

A 2006 study in the *Journal of Clinical Endocrinology & Metabolism* by Teichman and colleagues ran two randomised, placebo-controlled, double-blind trials in healthy adults aged 21 to 61. Participants received either single ascending doses or repeated weekly and fortnightly doses, over periods of 28 and 49 days.

Growth hormone and IGF-1 — the downstream hormone that carries out most of growth hormone's effects — were elevated, and the elevation was sustained rather than brief.

A companion paper from the same year addressed the obvious worry. Growth hormone is normally released in pulses, and there was a reasonable concern that continuously stimulating the system would flatten that rhythm into a constant trickle, which is not how the body uses the hormone. It found that pulsatile secretion persisted during continuous stimulation.

The distinction that changes everything

Here is the detail most write-ups skip, and it matters more than anything else on this page.

The compound in those trials was CJC-1295 with DAC. DAC stands for Drug Affinity Complex — a modification that latches the peptide onto a blood protein so it stays in circulation for days rather than minutes. That is why the trial could dose weekly.

What is usually sold and discussed as "CJC-1295" in research circles is frequently the version without DAC, also called Modified GRF (1-29). It is the same core sequence with a much shorter half-life, typically measured in minutes.

They are not interchangeable, and the human trial data above applies to the DAC version. Anyone citing the Teichman results to describe the no-DAC compound is stretching the evidence past what it covers. If you are reading about this compound anywhere, the first thing worth establishing is which version is being discussed.

Why Ipamorelin specifically

There are several compounds that act on the ghrelin receptor. Ipamorelin is the one usually chosen for pairing, and the reason given is selectivity.

Older compounds in this class tended to raise cortisol and prolactin alongside growth hormone — stress and lactation hormones respectively, neither of which anyone was aiming for. Ipamorelin is described in the literature as producing a cleaner growth hormone response with less of that spillover.

It is also short-acting, which fits the pairing: a short sharp signal on one receptor, a sustained one on the other.

Because they are almost always researched together, they are supplied pre-blended as CJC-1295 + Ipamorelin, commonly researched at 100–200 mcg, five times per week, timed before sleep on an empty stomach. The timing follows the body's own rhythm — the largest natural pulse arrives in early sleep — and food, particularly carbohydrate, blunts the response.

What is still open

Long-term safety data in healthy adults does not exist. The trials above ran for weeks, not years.

Raising IGF-1 has theoretical implications for cell growth generally, which is a question that has been raised for growth hormone therapy in general and is not settled.

And the effects measured were hormonal — growth hormone and IGF-1 levels in blood. Whether those translate into the outcomes people actually care about, in healthy adults rather than deficient patients, is a separate question the trials did not ask.

Everything described here is supplied for laboratory research only, and is not for human or veterinary use.